PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Xalkori bags FDA green light for rare paediatric non-Hodgkin lymphoma

The US Food and Drug Administration (FDA) has approved Pfizer’s Xalkori (crizotinib) for the treatment of paediatric patients and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL).

This new approval will enable children and young adults with anaplastic lymphoma kinase (ALK)-positive ALCL to access the new treatment option in the US.

ALCL is a rare type of non-Hodgkin lymphoma (NHL) that accounts for around 30% of cases of NHL in young people – in addition, approximately 90% of ALCL cases in young people are ALK-positive.

The approval is based on results from Pfizer’s Study ADVL0912 which included 121 patients between the ages of one and 21. This included 21 patients with relapsed or refractory, systemic ALK-positive ALCL after at least one systemic treatment.

Patients treated with Xalkori demonstrated an objective response rate of 88% – among the 23 patients who achieved a response, 39% maintained their response for at least six months and 22% maintained their response for at least 12 months.

“We are proud to deliver the first biomarker-driven therapy for children and young adults with ALCL. Xalkori offers a meaningful new treatment option for young patients with relapsed or refractory ALK-positive ALCL,” said Chris Boshoff, chief development officer, oncology, Pfizer Global Product Development.

“Xalkori transformed the treatment of ALK-positive non-small cell lung cancer as the first biomarker-driven therapy for that disease, and this approval is a notable milestone in our journey to continue to follow the science to address cancers with significant unmet need,” he added.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026